ACTIGRAFT INTENDED USE
ActiGraft is topically applied for the management of exuding cutaneous wounds, such as leg
ulcers, pressure ulcers, diabetic ulcers, and mechanically or surgically-debrided wounds.
FEATURES & BENEFITS
Provides significant savings in nursing costs and simplifies wound treatment.
Provides the wound with an optimal, natural healing environment allowing the healing process to proceed unhindered.
Can be easily prepared at the patient’s bedside in 8 minutes and requires no capital equipment
Uses the patient’s own blood to support the body’s own healing processes
EASE OF PAIN
Minimal handling of the wound provides a more comfortable treatment for patients
HOW ACTIGRAFT WORKS
RedDress’s ActiGraft® technology is revolutionizing the way we treat chronic wounds by managing each stage of the wound healing process. ActiGraft uses a patient’s own blood to create a whole blood clot tissue. This blood clot tissue is then applied to the wound, where it supports the natural healing processes of the body.
Hemostasis: The body works to stop the bleeding and start the healing process by activating a coagulation cascade. A fibrin blood clot forms that plugs severed blood vessels and fills in tissue discontinuity at the wound site.
Inflammation: During this phase, white blood cells and macrophages enter the wound
to destroy bacteria and remove debris. The blood clot creates a fibrin scaffold that serves as a protective, provisional extracellular matrix (ECM) containing cytokines and growth factors that facilitate tissue repair
Proliferation: The blood clot recruits endothelial cells and fibroblasts to synthesize a permanent ECM. The focus is filling and covering the wound.
Remodeling: The blood clot dries out and becomes a protective scab. Under the
scab, tissue remodeling takes place undisturbed. The fibrin is replaced by fibronectin and hyaluronan, and the scab falls off to reveal a collagenous scar
RECREATING THE NATURAL WOUND HEALING ENVIRONMENT WITH ACTIGRAFT
Evidence from clinical trials demonstrate high effectiveness in supporting the healing of hardto-treat wounds and ulcers with the use of an autologous blood clot.
• 72% of chronic wounds in
RedDress’ clinical trials had
• 62% area reduction at 4